Abstract
To investigate the prognostic significance of TGFβR2 expression and chemotherapy in Chinese non-small cell lung cancer (NSCLC) patients, TGFβR2 expression NSCLC was analyzed in silico using the Oncomine database, and subsequently analyzed with quantitative RT-PCR in 308 NSCLC biopsies, 42 of which were paired with adjacent non-neoplastic tissues. Our results show that TGFβR2 expression was also increased in NSCLC biopsies relative to normal tissue samples and correlated with poor prognosis. TGFβR2 expression was also significantly correlated with other clinical parameters such as tumor differentiation, invasion of lung membrane, and chemotherapy. Moreover, overall survival (OS) and disease free survival (DFS) was increased in patients with low TGFβR2 expressing NSCLC and who had undergone chemotherapy. Thus, high expression of TGFβR2 is a significant risk factor for decreased OS and DFS in NSCLC patients. Thus, TGFβR2 is a potential prognostic tumor biomarker for chemotherapy.
Highlights
Lung carcinoma is the leading cause of cancer-related mortality worldwide, accounting for 1.37 million deaths annually [1,2,3]
The results demonstrated that prognosis was worse for patients with lung adenocarcinoma where TGFβR2 expression was >1.99 fold higher than in normal tissues
These results indicated that high expression of TGFβR2 (> 1.99 fold) was associated with a poor prognosis in lung adenocarcinoma (Fig 1B)
Summary
Lung carcinoma is the leading cause of cancer-related mortality worldwide, accounting for 1.37 million deaths annually [1,2,3]. Non-small cell lung cancers (NSCLC) are the most common type of primary lung cancer, accounting for almost 80% of lung carcinoma [4]. Significant advances have taken place in our understanding of the disease process during the past few decades [5,6], the main treatment strategy is still surgical resection, chemotherapy, and PLOS ONE | DOI:10.1371/journal.pone.0134682. Youth Innovation Promotion Association, Chinese Academy of Sciences (Y219J11311) Significant advances have taken place in our understanding of the disease process during the past few decades [5,6], the main treatment strategy is still surgical resection, chemotherapy, and PLOS ONE | DOI:10.1371/journal.pone.0134682 August 7, 2015
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
